Breaking AI & Tech News Analyzed

Javokhir Sindarov sealed the men’s Candidates in Pegeia, Cyprus, with a historic 10 out of 14 points, finishing 1.5 points clear of Anish Giri. The 20‑year‑old Uzbek also posted the highest tally of six wins and eight draws since the current Candidates format began in 2013. In the women’s section, India’s Vaishali Rameshbabu claimed the title by a narrow ½‑point margin over Kazakhstan’s Bibisara Assaubayeva. Sindarov’s play evoked the classic Soviet master Mikhail Botvinnik, with meticulous opening preparation that often anticipated his opponents’ ideas deep into the endgame. When pressure mounted – notably in his second round against world No. 3 and US champion Fabiano Caruana – his defensive technique remained precise and confident. Final standings (14 rounds): Sindarov 10, Giri 8.5, Caruana 7.5, Wei Yi 7, Hikaru Nakamura 6.5, Praggnanandhaa Rameshbabu 6, Matthias Blübaum 6, Andrey Esipenko 4.5. The upcoming world championship match will be a best‑of‑14 showdown, pitting Sindarov against reigning champion Gukesh Dommaraju. Both will be 20 years old when the contest takes place in the second half of 2026, though the venue remains undecided. Gukesh’s recent dip to 15th in the ratings has added intrigue to the encounter. Analysts rate Sindarov as at least a 60 % favourite, while India’s grandmaster cohort – led by former champion Viswanathan Anand – is expected to rally behind Gukesh. Speculation also surrounds Magnus Carlsen, the current world No. 1, who stepped away from the classical crown in 2023. He indicated a willingness to defend only against Alireza Firouzja, but Firouzja’s recent focus on blitz and fashion has left the door open for a possible Carlsen‑Sindarov clash, should the Norwegian be persuaded. Sindarov’s rise is remarkable: he earned the grandmaster title at 12 years 10 months, later fell into a teenage obsession with the video game Counter‑Strike, and refocused on chess after defeating Firouzja at the 2021 World Cup. His resurgence helped Uzbekistan win gold at the 2022 Olympiad. Financial projections suggest a potential $10 million revenue stream for a Carlsen‑vs‑Sindarov title match, a figure that could also bolster Carlsen’s claim as the all‑time No. 1 ahead of Garry Kasparov. Nonetheless, Carlsen’s aversion to the intensive computer‑prep demanded by modern classical play remains a major hurdle. Carlsen may instead target the forthcoming 2027 FIDE World Total Championship Tour, which blends classical, rapid, and blitz formats, offering a more varied competitive landscape. In the Women’s Candidates, Vaishali Rameshbabu staged a stunning turnaround. After a 0‑5 start, she surged to the top after round 11, maintained a one‑point lead despite a round‑12 loss to China’s Zhu Jiner, and clinched the final round with a decisive victory over Kateryna Lagno in a sharp Sicilian Dragon, delivering the winning combination 39 Rd8+! 40 c4! Women’s final scores (14 rounds): Vaishali 8.5, Assaubayeva 8, Aleksandra Goryachkina 7.5, Zhu 7.5, Anna Muzychuk 7, Kateryna Lagno 6.5, Divya Deshmukh 5.5, Tan Zhongyi 5.5. Five‑time women’s world champion Ju Wenjun enters the upcoming title defence as a clear favourite, holding a peak rating above 2600 and currently rated 2559 against Vaishali’s 2470. Elsewhere, English GM Dan Fernandez posted an unbeaten 7/9 at the Menorca Open, achieving a 2601 performance rating and boosting his chances for selection to the England Olympiad squad. Young talents also featured: Argentina’s Faustino Oro and England’s Supratit Banerjee – both 12‑year‑olds – failed to secure their final GM norms, while India’s 10‑year‑old prodigy Aarit Kapil became only the fifth player ever to earn an IM norm before turning 11, later flirting with a historic GM norm. The English Chess Federation will host a 24‑hour chess marathon on Chess.com in memory of coaches GM Jonathan Hawkins and IM Adam Hunt, with proceeds supporting Macmillan Cancer Support. 4020: 1…Bxd4! 2 cxd4 Nf4! 3 Qb3 Qxf1+! 4 Kxf1 Rc1+ 5 Qd1 Rxd1 #

Angelina Jolie leads the new fashion‑driven drama Couture, bringing a rare level of personal honesty by confronting a storyline that mirrors her own double mastectomy performed to prevent breast cancer. While her performance is undeniably courageous, the film’s overall execution falls short of its ambitions.The plot follows Maxine, an American indie filmmaker (Jolie) who arrives in Paris to direct the opening short for a prestigious runway show. She discovers, through a compassionate doctor played by Vincent Lindon, that a recent biopsy confirms she has breast cancer, forcing her to consider postponing or abandoning her next project. Jolie conveys the shock and denial with subtlety, yet the script, penned by director Alice Winocour, often lapses into glib dialogue that undermines the emotional weight of the situation.Supporting characters include Ada, a fledgling South Sudanese model (Anyier Anei), makeup‑artist‑turned‑writer Angèle (Ella Rumpf), and the brooding first‑assistant director Anton (Louis Garrel). Their subplots—most notably Ada’s ankle injury that threatens the runway performance—remain underdeveloped, serving more as decorative set‑pieces than integral narrative threads.Visually, the film captures the glamour of Parisian haute couture with polished cinematography, yet this sheen accentuates the story’s lack of depth. The fashion world is presented with a “precious” aesthetic that feels specious, offering little insight beyond surface‑level allure.Despite these shortcomings, Jolie’s star power shines through. Her willingness to align a fictional role with a deeply personal health battle adds a layer of authenticity that the surrounding screenplay fails to sustain. ‘Couture’ will be available on digital platforms from 20 April, offering audiences a chance to appreciate Jolie’s performance even if the film’s broader ambitions remain unfulfilled.

Chris Walton, a renowned biologist and lecturer at Cranfield University, has passed away at the age of 69 due to brain cancer. He was widely respected for his pragmatic approach to getting things done and was often referred to as an honorary engineer by his colleagues.Walton's research focused on volatile organic compounds (VOCs) in various matrices, including breath, sweat, blood, urine, and faeces. He discovered links between specific VOCs and different human diseases, developing new methods to measure them. His work on environmental sensors, particularly low-cost air-quality monitors, was also notable.Born in Batley, West Yorkshire, Walton was the first in his family to attend university, graduating from Leicester University with a degree in biology in 1978. He later earned an MSc in biological computation at York University and a PhD from Coventry University.Walton's career spanned various institutions, including Imperial College London and EDS, an IT service provider. He joined Cranfield University in 1998 and became a lecturer in analytical technology. He was known for his sympathetic ear for students and his wise advice to younger colleagues.Walton is survived by his partner, Lorraine Morgan, and his daughter, Elizabeth.

The NAACP has filed a lawsuit against Elon Musk's artificial intelligence company, xAI, alleging that it has been illegally spewing toxic pollutants into Black neighborhoods near Memphis. The lawsuit claims that xAI's makeshift power plant in Southaven, Mississippi, has been operating without permits, violating the Clean Air Act.The suit, filed on Tuesday in Mississippi federal court, alleges that xAI has been polluting the surrounding historically Black communities by using dozens of methane gas generators without permits. The organization is seeking to force the company to stop operating its unpermitted turbines in Southaven.“All too often, big corporations like xAI treat our communities and families like obstacles to be pushed aside,” said Derrick Johnson, the president and CEO of the NAACP. “We will not allow xAI to get away with this.”xAI's datacenters, nicknamed “Colossus” and “Colossus II” by Musk, are massive facilities, with the latter occupying 1m sq ft in Memphis. They are located in Memphis's industrial zone and a few miles from residential neighborhoods that have long dealt with harmful pollution, including Boxtown, a neighborhood that was established by formerly enslaved people after emancipation in the 19th century.The lawsuit alleges xAI illegally installed and operated up to 27 gas turbines, each one the size of a large bus, to power the datacenters. Combined, they have the capacity to emit tons of harmful nitrogen oxides per year, along with toxic chemicals like formaldehyde, according to the Southern Environmental Law Center.xAI issued a statement in response to the lawsuit: “We take our commitment to the community and environment seriously. The temporary power generation units are operating in compliance with all applicable laws.” The company did not respond to questions about whether it will address the alleged violations listed in the lawsuit.Black residents still make up a large portion of the Memphis neighborhoods, which have faced higher rates of asthma and respiratory diseases as well as a lower life expectancy than other parts of the city. Studies have likewise shown these neighborhoods have a cancer risk that is four times the national average.

Metabolic liver disease, or MASLD, is projected to affect 1.8 billion people worldwide by 2050, according to a recent study. This significant increase is primarily driven by rising obesity and blood sugar levels globally.MASLD, previously known as non-alcoholic fatty liver disease (NAFLD), is one of the most prevalent and rapidly growing liver conditions worldwide. The condition's prevalence has already seen a 143% increase in just three decades, from 500 million people in 1990 to 1.3 billion people in 2023.The study, published in the Lancet Gastroenterology & Hepatology journal, highlights that high blood sugar is the leading driver of MASLD-related health problems globally, followed by high BMI and smoking. These factors are strongly linked to type 2 diabetes and obesity.Regional disparities exist, with north Africa and the Middle East having disproportionately higher rates of MASLD. However, there have been sharp increases in the number of people affected in countries across the world, including the UK, Australia, and the United States.Despite the growing number of cases, the overall impact on health has remained stable, suggesting that advances in treatment and care are helping people live longer and healthier lives. However, the increasing number of cases still poses a risk of serious complications such as liver cirrhosis or cancer in the future.

For the first time, thousands of cancer patients from Black and minority ethnic backgrounds will benefit from an enhanced genetic test offered by the NHS. The new screening expands the panel of DPYD gene variants from four to five, directly addressing a long‑standing bias that left non‑white patients vulnerable to dangerous chemotherapy side‑effects. In England, patients slated for chemotherapy undergo a genetic check that can guide dose adjustments and mitigate adverse reactions such as mouth sores, hair loss, nausea, fatigue, and, in severe cases, death. Up to 40% of the 38,000 individuals receiving fluoropyrimidine‑based chemotherapy each year experience a harmful drug reaction. Previously, the test only targeted four DPYD variants common in people of European descent, meaning many Black patients received inaccurate “all‑clear” results. The addition of a fifth variant—more prevalent among African, Caribbean and other minority groups—means clinicians can now identify patients at risk who were previously missed. Since its rollout at Manchester University NHS Foundation Trust last September, three minority‑ethnic patients have had their initial chemotherapy doses adjusted, lowering their chance of a potentially fatal reaction. Dr Veline L’Esperance, senior clinical adviser at the NHS Race and Health Observatory, called the change “tangible results for patients who have historically been left behind.” She emphasized that the update shifts the discussion on ethnic health inequality from rhetoric to actionable care. Prof Habib Naqvi, chief executive of the NHS Race and Health Observatory, described the development as a “groundbreaking outcome” for chemotherapy safety, while noting that ethnic minorities remain under‑represented in genomic research and biobanks. He warned that broader inclusion is essential for the promised benefits of precision medicine to reach all communities. Prof Dame Sue Hill, chief scientific officer for NHS England, highlighted the significance of discovering the fifth variant: “Personalising chemotherapy based on genetics can save lives and reduce harmful side‑effects, especially for patients of African ancestry.” She added that the North West NHS Genomic Medicine Service has already demonstrated the practical impact of this approach. These steps come amid broader evidence that minority patients in the UK face longer diagnostic waits, more GP visits before a cancer diagnosis, and lower perceived support during treatment. The expanded DPYD test represents a concrete effort to close those gaps and ensure equitable, science‑driven care for all cancer patients.

Sam Neill, the veteran actor celebrated for his memorable performances on screen, is set to answer readers' questions in an upcoming interview with The Guardian. Neill's iconic roles include his portrayal in Jurassic Park, where he famously removes his sunglasses and gazes at a towering Brachiosaurus, a scene that has become etched in cinematic history.Born in Northern Ireland and raised in New Zealand, Neill's diverse filmography showcases his versatility as an actor. He has appeared in a range of films, from period dramas like My Brilliant Career to thrillers such as Dead Calm, which is set to be released in 4K later this year. His recent projects include Godzilla x Kong: Supernova, alongside Kaitlyn Dever and Matthew Modine.Neill's career has been marked by his ability to take on idiosyncratic, director-led projects, often playing characters with a unique blend of gruffness and warmth. His performances in Sweet Country and Rams have been particularly noted for their depth and nuance.In addition to his film work, Neill has also made headlines for his memoir, Did I Ever Tell You This?, in which he openly discusses his experience with stage-three blood cancer and his journey towards remission. When asked about his mortality, Neill expressed a pragmatic view, stating, “I’m not afraid to die, but it would annoy me”.Readers are invited to post their questions for Sam Neill by 6pm BST, Thursday 16 April, and The Guardian will publish his answers in their reader interview series. This provides a unique opportunity for fans to engage with one of cinema's most beloved actors and gain insight into his life and career.

Scientists at London's Institute of Cancer Research and the RCSI University of Medicine and Health Sciences in Dublin have announced a new AI-driven approach to identify how patients with advanced bowel cancer will respond to bevacizumab, a drug recently introduced by the NHS. The method uses PhenMap, an AI tool that integrates complex data on the genetic makeup of tumors, allowing researchers to track patterns of how different patients react to the drug. This development aims to spare potentially thousands of patients from being given drugs that would be ineffective in fighting their cancers. In the UK alone, nearly 10,000 cases of advanced bowel cancer are identified every year, with young adults seeing a particular rise in diagnoses. Bowel cancer has the second-highest mortality rate of any cancer, behind only lung cancer. While survival rates can be as high as 98% when caught early, the five-year survival rate for advanced bowel cancer can be as low as 10%. The study tracked 117 European bowel cancer patients who had been treated with chemotherapy and bevacizumab. Researchers identified a group of patients who all had the same gene mutation and were at a high risk of having negative reactions. The scientists behind the tests now hope to expand the number of patient samples and see if the results can be used in treatments for other types of cancer. Anguraj Sadanandam, a professor in stratification and precision medicine at the ICR, said: “Once bowel cancer spreads to other parts of the body, there are very few treatment options available for patients. It is therefore positive that patients can now access the targeted drug bevacizumab on the NHS. However, we know that the majority of patients won’t benefit from the drug, meaning thousands of people in England could be facing unpleasant side effects unnecessarily.” Sadanandam added that while the findings were encouraging, the tool would need to be tested on a larger cohort to be validated. “In future, I hope this approach will lead to a test that can be used by clinicians, to ensure patients receive personalised care that has the highest chance of working against their cancer.”

GSK has revealed promising early results for its treatment for gynaecological cancers, Mocertatug Rezetecan (Mo-Rez), as its chief executive, Luke Miels, seeks to speed up drug development at the group.The company reported that in an early-stage trial, Mo-Rez shrank or eliminated tumours in 62% of patients with ovarian cancer where chemotherapy had failed, and in 67% of those with endometrial cancer.GSK acquired the Mo-Rez cancer treatment, an antibody-drug conjugate (ADC), from China’s Hansoh Pharma in late 2023, and has trialled it in 224 patients around the world, including the UK, over the past year. Few patients needed to stop treatment because of side-effects, the most common being nausea. It is administered every three weeks via intravenous infusion.Combined with data from a separate, intermediate trial in China, these results give GSK the confidence to go straight to late-stage trials, with five clinical studies planned globally in the next few months, including on patients in the UK.Presenting the results at the Society of Gynecologic Oncology’s annual meeting on women’s cancer in Puerto Rico, Hesham Abdullah, GSK’s global head of cancer research and development, said: “Treatment of gynaecological cancers remains a major challenge, with a pressing need for new therapies that offer improved response rates. With Mo-Rez we now have compelling evidence of a promising clinical profile.”Endometrial cancer affects 1.6 million women globally, with 417,000 new cases each year. Ovarian cancer affects 843,000 people, with 240,000 new cases annually.Abdullah described Mo-Rez as a “key asset” in the company’s growing cancer portfolio, expected to be a blockbuster drug with peak annual sales of more than £2bn, which GSK hopes will help it achieve its 2031 sales target of £40bn.